{"product_id":"pasg-vrio-analysis","title":"Passage Bio, Inc. (PASG): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Passage Bio, Inc. (PASG) truly built to last? This VRIO analysis distills the essence of their competitive edge, scrutinizing whether their core assets are Valuable, Rare, Inimitable, and Organized for sustained success. Dive in now to see the definitive verdict on their market dominance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePassage Bio, Inc. (PASG) - VRIO Analysis: 1. PBFT02 Clinical Program for FTD-GRN\/C9orf72\n\u003c\/h2\u003e\n\n\u003cp\u003eYou are looking at the core asset for Passage Bio, Inc. (PASG), the PBFT02 gene therapy, and trying to figure out if it’s a durable winner in the crowded neurodegenerative space. Honestly, the near-term story is all about clinical execution and regulatory milestones, not just the science itself.\u003c\/p\u003e\n\n\u003cp\u003eThe good news is that as of their Q3 2025 report on November 10, 2025, Passage Bio is actively pushing the upliFT-D study forward. They are enrolling patients in Cohort 3 for FTD-GRN and Cohort 4 for FTD-C9orf72, both groups receiving Dose 2 of PBFT02. Specifically, Cohort 3 is expected to enroll between \u003cstrong\u003e5\u003c\/strong\u003e and \u003cstrong\u003e10\u003c\/strong\u003e FTD-GRN patients, while Cohort 4 is smaller, targeting \u003cstrong\u003e3\u003c\/strong\u003e to \u003cstrong\u003e5\u003c\/strong\u003e FTD-C9orf72 patients.\u003c\/p\u003e\n\n\u003cp\u003eThe company has also made significant strides in manufacturing, which directly impacts future scalability and cost. They aligned with the U.S. Food and Drug Administration (FDA) on an analytical plan to prove comparability for a new, high-productivity, suspension-based manufacturing process. This new process is estimated to yield over \u003cstrong\u003e1,000\u003c\/strong\u003e doses at Dose 2 with over \u003cstrong\u003e90%\u003c\/strong\u003e purity and over \u003cstrong\u003e70%\u003c\/strong\u003e full capsids from a single batch.\u003c\/p\u003e\n\n\u003cp\u003eFinancially, you need to keep an eye on the burn rate. As of September 30, 2025, the cash position stood at \u003cstrong\u003e$52.8 million\u003c\/strong\u003e, which they project funds operations into the first quarter of 2027. Their net loss for Q3 2025 was \u003cstrong\u003e$7.7 million\u003c\/strong\u003e. That runway gives them time, but success hinges on the next set of data.\u003c\/p\u003e\n\n\u003ch3\u003eVRIO Framework Assessment for PBFT02\u003c\/h3\u003e\n\u003cp\u003eHere’s the quick math on how this asset stacks up using the VRIO lens. This framework helps us see if the therapy’s inherent qualities can translate into a lasting market edge.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO Dimension\u003c\/th\u003e\n    \u003cth\u003eAssessment\u003c\/th\u003e\n    \u003cth\u003eSupporting Context\/Data\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eValue (V)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eOffers a potential one-time, disease-modifying therapy for devastating FTD mutations, addressing a high unmet medical need. Interim data shows robust, durable elevation of CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eRarity (R)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eRare\u003c\/td\u003e\n    \u003ctd\u003eFew therapies are this advanced for these specific, devastating neurodegenerative causes (FTD-GRN\/C9orf72).\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eImitability (I)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eModerate\u003c\/td\u003e\n    \u003ctd\u003eThe specific clinical data, patient cohort progress (now enrolling FTD-C9orf72), and the FDA-aligned high-productivity manufacturing process are hard to replicate quickly.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eOrganization (O)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eThe company is actively enrolling Cohorts 3 and 4, showing focused execution, and has aligned with the FDA on a registrational pathway path for FTD-GRN, targeting feedback in 1H 2026.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eTemporary\u003c\/td\u003e\n    \u003ctd\u003eSustained advantage depends on positive pivotal trial results and subsequent FDA acceptance of the registrational design.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the risk associated with the protocol amendment. The trial was updated to include prophylactic anticoagulation after serious adverse reactions (SAEs) related to blood clot formation were observed in \u003cstrong\u003e3\u003c\/strong\u003e of \u003cstrong\u003e8\u003c\/strong\u003e treated people in the study. This shows the organization is responsive, but it’s a hurdle that needs to be cleared for broader adoption.\u003c\/p\u003e\n\n\u003cp\u003eThe path to a sustained advantage requires translating these encouraging biomarker signals into clear clinical benefit data. The next major catalyst is the planned regulatory feedback on the FTD-GRN registrational trial design, which Passage Bio is on track to seek in the first half of 2026.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSeek regulatory feedback on FTD-GRN registrational trial design in \u003cstrong\u003e1H 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eInterim safety and biomarker data from Dose 2 expected in \u003cstrong\u003e1H 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash runway supports operations into \u003cstrong\u003e1Q 2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: review the \u003cstrong\u003e$52.8 million\u003c\/strong\u003e Q3 2025 cash balance against the 1H 2026 data readout timeline by next Tuesday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePassage Bio, Inc. (PASG) - VRIO Analysis: 2. High-Productivity Suspension-Based Manufacturing Process\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003ePromises a lower Cost of Goods (COGS) and scalability. The GMP-ready, suspension-based manufacturing process for PBFT02 has been executed at 200-liter scale. This process yields product with over 90% purity and over 70% full capsids per batch, representing a substantial improvement over the current adherent-based manufacturing process. The company reported a cash position of $52.8 million as of September 30, 2025, which is expected to fund operations into 1Q 2027.\u003c\/p\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eRare; achieving this scale and purity in AAV manufacturing is a significant technical hurdle, especially transitioning from adherent to suspension culture. The successful execution at 200-liter scale demonstrates a current capability that is not widely achieved across the industry for all AAV programs.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eHigh; process chemistry and manufacturing know-how (CMC) are often proprietary and complex to copy. The transition and optimization to a high-productivity suspension process involves specialized knowledge and significant development time.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eHigh; they have aligned with the FDA on an analytical plan to establish process comparability for the suspension-based process. The company reported a net loss of $7.7 million for the quarter ended September 30, 2025, reflecting a focused operational structure.\u003c\/p\u003e\n\u003cp\u003eSupporting operational and financial metrics as of September 30, 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents and marketable securities: $52.8 million.\u003c\/li\u003e\n\u003cli\u003eNet loss for Q3 2025: $7.7 million.\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) Expenses for Q3 2025: $4.3 million.\u003c\/li\u003e\n\u003cli\u003eGeneral and Administrative (G\u0026amp;A) Expenses for Q3 2025: $4.3 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe VRIO assessment for the manufacturing process is summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Component\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Data\/Metric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh Potential\u003c\/td\u003e\n\u003ctd\u003eExecution at 200-liter scale; Over 90% purity; Over 70% full capsids.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eRare\u003c\/td\u003e\n\u003ctd\u003eSignificant technical hurdle in AAV manufacturing.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eProprietary process chemistry and CMC know-how.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eAlignment with FDA on analytical comparability plan.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained; superior manufacturing efficiency provides a long-term cost and supply advantage if the therapy is approved. The improved productivity and purity metrics directly impact the potential Cost of Goods Sold (COGS) per dose.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePassage Bio, Inc. (PASG) - VRIO Analysis: 3. Demonstrated Durability of Progranulin (PGRN) Expression\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Clinical data from Dose 1 showed robust and durable elevation of CSF PGRN expression through \u003cstrong\u003e18 months\u003c\/strong\u003e post-treatment, suggesting long-lasting therapeutic effect. Plasma NfL levels showed a 13% reduction at 12 months post-treatment versus an expected 29% annual increase in untreated patients.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare; long-term durability data in CNS gene therapy is a key differentiator. Sustained elevation of CSF PGRN beyond 12 months is a key data point.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; while the AAV vector is known, achieving this specific, sustained expression profile is not guaranteed for competitors. The use of the AAV1 vector is noted.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this data directly informs their engagement with health authorities, with plans to seek regulatory feedback on the FTD-GRN pivotal trial design in 1H 2026. The company's cash runway extends into Q1 2027.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this advantage erodes if newer, more durable therapies emerge, but it’s a strong near-term asset. The company reported a cash position of $57.6 million as of Q2 2025.\u003c\/p\u003e\n\u003cp\u003eThe quantitative demonstration of PGRN expression durability is summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTime Point\u003c\/th\u003e\n\u003cth\u003eCSF PGRN Level (Dose 1 PBFT02)\u003c\/th\u003e\n\u003cth\u003ePatient Count (n)\u003c\/th\u003e\n\u003cth\u003eReference\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBaseline\u003c\/td\u003e\n\u003ctd\u003eBelow \u003cstrong\u003e3 ng\/mL\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eVaries (e.g., n=7 at 1 month)\u003c\/td\u003e\n\u003ctd\u003eAll patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e1 Month\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMean of \u003cstrong\u003e12.4 ng\/mL\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePost-treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e6 Months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13 – 27 ng\/mL\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported range\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e12 Months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22 – 34 ng\/mL\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported range\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e18 Months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMean of \u003cstrong\u003e23.8 ng\/mL\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDurable expression\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthy Adult Control\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3.3 to 8.2 ng\/mL\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e61\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReference range\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organizational context is supported by financial metrics demonstrating resource management to reach key milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents and marketable securities as of Q2 2025: \u003cstrong\u003e$57.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eProjected cash runway into \u003cstrong\u003eQ1 2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) Expenses for Q2 2025: \u003cstrong\u003e$5.8 million\u003c\/strong\u003e, compared to $10.4 million year-over-year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePassage Bio, Inc. (PASG) - VRIO Analysis: 4. Specialized Intracisternal Magna (ICM) Delivery Expertise\n\u003c\/h2\u003e\n\u003cp\u003eThe ICM injection route is designed to deliver the AAV1 vector directly to the cerebrospinal fluid (CSF) for targeted CNS delivery.\u003c\/p\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe ICM injection route is designed to deliver the AAV1 vector directly to the cerebrospinal fluid (CSF) for targeted CNS delivery.\u003c\/p\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; while ICM is known, the company’s experience executing this procedure across multiple cohorts is valuable. This experience includes treating patients in the Imagine-1 study for GM1 and the upliFT-D study for FTD-GRN.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eModerate; requires specialized surgical\/procedural expertise that others must develop. Preclinical studies in non-human primates demonstrated that a single ICM administration of PBFT02 led to broad vector distribution throughout the CNS, with AAV1 being particularly proficient at transducing ependymal cells.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eHigh; this is the established, consistent delivery method for their lead program. ICM is the delivery method for their first \u003cstrong\u003ethree\u003c\/strong\u003e clinical trials.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary; other delivery methods could prove superior or easier to scale later on. Clinical data supports the method's efficacy and safety profile to date.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eVector\/Therapy\u003c\/th\u003e\n\u003cth\u003ePatient Cohorts Treated\u003c\/th\u003e\n\u003cth\u003eICM Safety Observation\u003c\/th\u003e\n\u003cth\u003eBiomarker Efficacy Metric (ICM-related)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGM1 Gangliosidosis\u003c\/td\u003e\n\u003ctd\u003ePBGM01 (AAVhu68)\u003c\/td\u003e\n\u003ctd\u003eCohorts 1-4 (as of August 2023)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eNo\u003c\/strong\u003e complications related to ICM delivery in Cohort 1 low dose late infantile patients.\u003c\/td\u003e\n\u003ctd\u003eDose 2 achieved healthy control levels of $\\beta$-Gal activity in CSF, with durability up to \u003cstrong\u003e12 months\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFTD with GRN Mutations\u003c\/td\u003e\n\u003ctd\u003ePBFT02 (AAV1)\u003c\/td\u003e\n\u003ctd\u003eDose 1 ($n=7$ as of June 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eNo\u003c\/strong\u003e complications during ICM administration observed across any of the \u003cstrong\u003eeight\u003c\/strong\u003e treated patients (as of June 2025).\u003c\/td\u003e\n\u003ctd\u003eDose 1 increased CSF PGRN from below \u003cstrong\u003e3 ng\/mL\u003c\/strong\u003e at baseline to \u003cstrong\u003e13 – 27 ng\/mL at six months\u003c\/strong\u003e ($n=4$).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSpecific data points reinforcing the established nature of the ICM delivery expertise:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFor PBGM01 in the Imagine-1 study, Dose 2 resulted in a \u003cstrong\u003e4.7-16.1x\u003c\/strong\u003e increase in CSF $\\beta$-Gal activity at \u003cstrong\u003e30 days\u003c\/strong\u003e post-treatment relative to baseline in \u003cstrong\u003e3 of 4\u003c\/strong\u003e children.\u003c\/li\u003e\n\u003cli\u003eFor PBFT02 in the upliFT-D study, Dose 1 treatment resulted in a robust and durable increase in CSF PGRN expression through \u003cstrong\u003e18 months\u003c\/strong\u003e post-treatment in \u003cstrong\u003eall\u003c\/strong\u003e patients treated with Dose 1.\u003c\/li\u003e\n\u003cli\u003eIn the upliFT-D study, \u003cstrong\u003e2 of 7\u003c\/strong\u003e patients experienced a total of \u003cstrong\u003e3 serious adverse events (SAEs)\u003c\/strong\u003e, none of which were related to ICM administration.\u003c\/li\u003e\n\u003cli\u003eThe clinical trial upliFT-D is a \u003cstrong\u003etwo-year\u003c\/strong\u003e clinical trial with a \u003cstrong\u003ethree-year\u003c\/strong\u003e safety extension.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePassage Bio, Inc. (PASG) - VRIO Analysis: 5. Focused Pipeline on Neurodegenerative CNS Disorders\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Deep focus on FTD, ALS, and Huntington’s Disease (HD) allows for concentrated scientific and operational resources.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many biotechs have broad pipelines, but Passage Bio is specifically targeting the underlying pathology of these severe CNS conditions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the scientific knowledge base is accessible, but the specific targets are hard to validate clinically.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the entire company mission is aligned around this therapeutic area.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; deep domain expertise in CNS disorders can lead to better future pipeline candidates.\u003c\/p\u003e\n\n\u003cp\u003eThe focus on severe neurodegenerative disorders targets markets with significant unmet need, as evidenced by the overall Central Nervous System therapeutics market size estimated at USD 130.1 billion in 2024, with the neurodegenerative diseases segment accounting for more than 40% of the market share in 2024.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eUS\/EU Prevalence (Reported)\u003c\/th\u003e\n\u003cth\u003eClinical Status (as of latest update)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBFT02\u003c\/td\u003e\n\u003ctd\u003eFrontotemporal Dementia - GRN\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePhase 1\/2 upliFT-D trial; 4 patients enrolled in Cohort 2 (as of Q3 2024).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBFT02\u003c\/td\u003e\n\u003ctd\u003eFrontotemporal Dementia - C9orf72\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e21,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePreclinical\/Advancing; Plan to initiate dosing in 1H 2025 (as of Jan 2025).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnnamed\u003c\/td\u003e\n\u003ctd\u003eAmyotrophic Lateral Sclerosis (ALS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e72,600\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePreclinical research program.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnnamed\u003c\/td\u003e\n\u003ctd\u003eHuntington's Disease (HD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePreclinical research program; HD affects approximately 1 in 10,000 people in the US.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eClinical data from the PBFT02 program in FTD-GRN demonstrated specific biomarker activity:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eDose 1 of PBFT02 treatment resulted in CSF progranulin (PGRN) levels increasing from below 3 ng\/mL at baseline to 13 – 27 ng\/mL at six months (n=4).\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCSF PGRN levels reached 22 – 34 ng\/mL at 12 months (n=2).\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eDose 2 is 50% lower than Dose 1.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinancial positioning supports continued execution:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and marketable securities were $84.8 million as of September 30, 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company expected this cash position to fund operations to the end of Q2 2026.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) Expenses for the quarter ended September 30, 2024, were $8.7 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePassage Bio, Inc. (PASG) - VRIO Analysis: 6. Lean, Outsourced Operational Structure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The January 2025 workforce reduction of about \u003cstrong\u003e55%\u003c\/strong\u003e, leaving roughly \u003cstrong\u003e26\u003c\/strong\u003e employees, and transition to outsourced analytical testing extends the cash runway.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eWorkforce size reduced from 58 employees (as of December 31, 2023) to approximately 26 employees.\u003c\/li\u003e\n\u003cli\u003eExpected associated severance and exit costs of about $2 million primarily during the second quarter of 2025.\u003c\/li\u003e\n\u003cli\u003eThe cash runway was extended into the first quarter of 2027 as a result of the measures.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare in this specific context; it’s a deliberate, recent strategic pivot for survival and focus.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a specific organizational choice based on past financial performance.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this structure is explicitly designed to support operations into 1Q 2027.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this lean model is only advantageous as long as outsourced partners perform well and internal expertise remains sufficient.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (as of latest report)\u003c\/td\u003e\n\u003ctd\u003eContext\/Comparison\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce Size\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e26\u003c\/strong\u003e employees\u003c\/td\u003e\n\u003ctd\u003eDown from 58 employees (as of December 31, 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Projection\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e1Q 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eExtended from end of Q2 2026 (prior projection)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Mkt. Sec.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$52.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (QoQ)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDown from $8.7 million (Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A Expenses (QoQ)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDown from $7.3 million (Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeverance\/Exit Costs\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$2 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eIncurred primarily in Q2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing Yield Estimate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;1,000 doses\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFrom \u003cstrong\u003e200-L\u003c\/strong\u003e suspension run\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents and marketable securities were $76.8 million as of December 31, 2024.\u003c\/li\u003e\n\u003cli\u003eThe 200-L suspension-based manufacturing process produced a batch estimated to yield \u0026gt;1,000 doses at \u0026gt;90% purity and \u0026gt;70% full capsids.\u003c\/li\u003e\n\u003cli\u003eQ3 net loss was $7.7 million ($2.44 per share, post 1-for-20 reverse split) for Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePassage Bio, Inc. (PASG) - VRIO Analysis: 7. Positive Biomarker Signal (Plasma NfL Improvement)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003cstrong_\u003eValue:\u003c\/strong_\u003e Improvement in plasma Neurofilament Light Chain (NfL), a well-characterized disease progression biomarker, provides objective evidence of therapeutic effect.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong_\u003eRarity:\u003c\/strong_\u003e Moderate; showing a clear impact on a validated biomarker is a strong signal in early-stage CNS trials.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong_\u003eImitability:\u003c\/strong_\u003e Moderate; replicating the specific dose-response relationship with NfL is challenging.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong_\u003eOrganization:\u003c\/strong_\u003e High; this data is central to their upcoming regulatory discussions.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong_\u003eCompetitive Advantage:\u003c\/strong_\u003e Temporary; this advantage is contingent on the biomarker remaining predictive and relevant as the trial progresses.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePassage Bio (PBFT02 Dose 1)\u003c\/th\u003e\n\u003cth\u003eNatural History (Untreated FTD-GRN)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlasma NfL Increase at 12 Months\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4%\u003c\/strong\u003e (n=4)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e28%\u003c\/strong\u003e to \u003cstrong\u003e29%\u003c\/strong\u003e per year (n=11 or n=15)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nThe objective evidence supporting the therapeutic effect includes:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePlasma Neurofilament Light Chain (NfL) levels increased by \u003cstrong\u003e4%\u003c\/strong\u003e on average at \u003cstrong\u003e12 months\u003c\/strong\u003e post-treatment (n=4).\u003c\/li\u003e\n\u003cli\u003eThis compares to an expected increase of \u003cstrong\u003e28%\u003c\/strong\u003e and \u003cstrong\u003e29%\u003c\/strong\u003e per year in untreated symptomatic FTD-GRN patients based on ALLFTD natural history data (n=11) and published natural history data (n=15), respectively.\u003c\/li\u003e\n\u003cli\u003ePassage Bio plans to seek regulatory feedback on the FTD-GRN pivotal trial design in \u003cstrong\u003e1H 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePassage Bio, Inc. (PASG) - VRIO Analysis: 8. Clear Path to Registrational Trial Feedback\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe company is on track to seek regulatory feedback on the FTD-GRN registrational trial design in the 1H 2026.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nModerate; having a defined, actionable next step with the FDA is a major de-risking event.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nLow; this is a function of regulatory process, not an internal asset, though the data package is proprietary.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nHigh; the entire R\u0026amp;D and regulatory teams are geared toward this 1H 2026 goal, supported by ongoing clinical execution.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nCohort 3 (FTD-GRN) expected to consist of five to 10 patients.\n\u003c\/li\u003e\n\u003cli\u003e\nDose 2 PBFT02 resulted in CSF PGRN levels reaching the upper limit of a healthy adult reference range.\n\u003c\/li\u003e\n\u003cli\u003e\nCash runway expected to fund operations into 1Q 2027.\n\u003c\/li\u003e\n\u003cli\u003e\nR\u0026amp;D Expenses for Q2 2025 were $5.8 million.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary; once feedback is received, the advantage shifts to the company that executes the trial best.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Target\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegistrational Trial Feedback Target\u003c\/td\u003e\n\u003ctd\u003eSeek regulatory feedback\u003c\/td\u003e\n\u003ctd\u003e1H 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway End Point\u003c\/td\u003e\n\u003ctd\u003eFund operations into\u003c\/td\u003e\n\u003ctd\u003e1Q 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (as of)\u003c\/td\u003e\n\u003ctd\u003e$57.6 million\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFTD-GRN Cohort 3 Size (Expected)\u003c\/td\u003e\n\u003ctd\u003e5 to 10 patients\u003c\/td\u003e\n\u003ctd\u003eOngoing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e$5.8 million\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e$9.4 million\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003ePassage Bio, Inc. (PASG) - VRIO Analysis: 9. Financial Runway into 1Q 2027\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e With cash, cash equivalents, and marketable securities of \u003cstrong\u003e$52.8 million\u003c\/strong\u003e as of September 30, 2025, the company has the capital to reach key 2026 milestones without immediate dilution.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many clinical-stage biotechs struggle with cash runway beyond 12-18 months.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a direct result of past financing and recent cost-cutting measures.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the finance function successfully managed burn to achieve this runway.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this is a depleting asset that must be replenished or used before 1Q 2027.\u003c\/p\u003e\n\u003cp\u003eThe company's cash position as of September 30, 2025, is \u003cstrong\u003e$52.8 million\u003c\/strong\u003e, with an expected runway into \u003cstrong\u003e1Q 2027\u003c\/strong\u003e. This compares to \u003cstrong\u003e$84.8 million\u003c\/strong\u003e as of September 30, 2024.\u003c\/p\u003e\n\u003cp\u003eThe operational expenditure profile for the third quarter of 2025 demonstrates the current burn rate:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 (Ended 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003eQ3 2024 (Ended 9\/30\/2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$52.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$84.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development (R\u0026amp;D) Expenses (Quarterly)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral \u0026amp; Administrative (G\u0026amp;A) Expenses (Quarterly)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses (R\u0026amp;D + G\u0026amp;A)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Monthly Operating Expense (Based on Quarterly)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~$2.87 million\/month\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~$5.33 million\/month\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Quarterly)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe implied monthly burn rate based on the Q3 2025 operating expenses is approximately \u003cstrong\u003e$2.87 million\/month\u003c\/strong\u003e. The runway into 1Q 2027 (approximately 18 months from 9\/30\/2025) implies an average burn of approximately \u003cstrong\u003e$2.93 million\/month\u003c\/strong\u003e ($52.8M \/ 18 months).\u003c\/p\u003e\n\u003cp\u003eThe following sensitivity analysis models the impact of a 6-month delay in FDA feedback, which would necessitate funding operations for an additional 6 months beyond the stated 1Q 2027 runway, assuming the current Q3 2025 expense run rate of \u003cstrong\u003e$2.87 million\/month\u003c\/strong\u003e is maintained.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eScenario Parameter\u003c\/td\u003e\n\u003ctd\u003eBase Case (Stated Runway)\u003c\/td\u003e\n\u003ctd\u003eSensitivity Case (6-Month Delay)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStarting Cash (9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$52.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$52.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssumed Monthly Burn Rate\u003c\/td\u003e\n\u003ctd\u003e~$2.93 million\/month (Implied)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$2.87 million\/month\u003c\/strong\u003e (Based on Q3 2025 OpEx)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOriginal Runway End Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1Q 2027\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdditional Time to Fund\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Required for Additional 6 Months\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$17.22 million\u003c\/strong\u003e (6 months  $2.87M\/month)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Effective Runway End Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1Q 2027\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3Q 2027\u003c\/strong\u003e (1Q 2027 + 6 months)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Balance at Original 1Q 2027 End Date (If Delayed)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$0.00 million\u003c\/strong\u003e (Assuming cash is fully depleted by the new runway end)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunding Gap to Maintain 1Q 2027 Cash Level until 3Q 2027\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.22 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey milestones targeted for the period covered by the current runway include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReport updated interim safety and biomarker data from Dose 2 in \u003cstrong\u003e1H 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSeek regulatory feedback on registrational trial design in FTD-GRN in \u003cstrong\u003e1H 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe financial runway is directly tied to the execution timeline of the upliFT-D clinical trial and subsequent regulatory interactions.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516227248277,"sku":"pasg-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/pasg-vrio-analysis.png?v=1740204298","url":"https:\/\/dcf-model.com\/products\/pasg-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}